[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"global-developmental-delay\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:global-developmental-delay":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100648033","home-play-based-intervention-for-parents-and-infants-100648033",false,"NCT07716072","Home Play-based Intervention for Parents and Infants","Sociometric Play-based Remediation of Individual Neurodevelopmental Trajectories (SPRINT)","SPRINT","Inclusion Criteria:\n\nAll participants must satisfy the following criteria:\n\n* Parent(s) must have access to the internet via a computer, laptop or phone.\n* Parent (s) with adequate English comprehension skills to participate in the study tasks and provide consent\n\nParticipants will be included if they meet either of the following criteria:\n\n\\- Parent(s) with infants who are identified as having increased familial risk of ASD, ADHD, GDD, related neurodevelopmental disorders or premature birth outcomes. Prematurity is defined as being born before 37 weeks.\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet the following criteria:\n\n* Parent(s) and infants with brain injury, severe motor or sensory impairments (e.g., visual or hearing) that would render them unable to participate in the tasks\n* Parent(s) diagnosed to have impaired intellectual functioning or mental capacity.\n* Infants with an identified genetic, metabolic, syndromic, or progressive neurological disorder (e.g., epilepsy, Down or Rett Syndrome, Tuberous Sclerosis, Neurofibromatosis, Fragile X Syndrome), including vascular risk factors\n* Parent (s) with current or pre-existing diagnosed psychological conditions.","ALL","9 Months","15 Months",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn whether a 12-week home-based intervention (Sociometric Play-based Remediation of Individual Neurodevelopmental Trajectories (SPRINT)) helps support parenting and the development of infants aged 7 - 15 months (at the time they join the study) who were born preterm and\u002For have a higher family risk of developmental conditions, such as autism spectrum disorder (ASD), attention-deficit\u002Fhyperactivity disorder (ADHD), and\u002For global developmental delay (GDD). The main questions it aims to answer are:\n\n* Does taking part in the SPRINT intervention help parents develop parenting skills?\n* Does taking part in the SPRINT intervention improve infant's thinking skills and\u002For socio-emotional development?\n\nResearchers will compare families who receive the SPRINT intervention with families in a waitlist control group to see whether the intervention leads to greater improvements in parents and their children.\n\nParticipants will:\n\n* Complete questionnaires and in-person assessments, before and after the 12-week period.\n* Be assigned to either the SPRINT intervention or a waitlist control group and complete the assigned activities for 12 weeks.\n* Use the SPRINT app, which provides information, guidance and activities for either the SPRINT intervention or waitlist control group.",[28,29,30,31],"Attention-Deficit\u002FHyperactivity Disorder (ADHD)","Autism Spectrum Disorder","Premature Birth","Global Developmental Delay",[33,34,35,36,37,38,39],"Intervention","At-Risk Cohort","Play-based","Home","Social Emotional","Executive Function","Emotional Regulation","NOT_YET_RECRUITING","2026-07-16",{"date":43,"type":44},"2026-07-21","ACTUAL",{"date":46,"type":22},"2026-07",{"date":48,"type":22},"2030-03",{"name":50,"class":51},"Nanyang Technological University","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":52},"100621387","repetitive-transcranial-magnetic-stimulation-combined-with-language-training-for-language-disorders-in-children-with-global-developmental-delay-100621387","NCT07369960","Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Global Developmental Delay","Randomized Controlled Study for Repetitive Transcranial Magnetic Stimulation Combined With Language Training in Children With Language Disorders in Children With Global Developmental Delay","Inclusion criteria\n\n1. Children aged 2-5 years old, regardless of gender.\n2. Meet the diagnostic definition of GDD in China's Diagnostic Guidelines for Global Developmental Delay (2024), confirmed by Gesell Developmental Schedules (GDS). Language domain Developmental Quotient (DQ) ≤ 75. A DQ ≤ 75 is found in at least one of the four developmental domains: gross motor, fine motor, adaptive behavior, and personal-social conduct. Mild-moderate GDD is selected for the study.\n3. The presence of significant language developmental delay, the language ability is significantly lower than children of the same age and the same intellectual level, confirmed by the standardized scale of Sign-Significate Relations (S-S) assessment.\n4. The child is able to cooperate with the completion of rTMS treatment and language assessment and has no serious behavioral problems.\n5. Written informed consent obtained from the child's legal guardian. Exclusion Criteria\n\n1\\. History of epilepsy or convulsive seizures. 2. Having metal implants in the skull (e.g. aneurysm clips, metal stents, etc.) and electronic devices such as pacemakers and cochlear implants in the body.\n\n3\\. Other serious neurological conditions that may affect language function (e.g., cerebral palsy, progressive neurological disorders, etc.).\n\n4\\. Have a diagnosis of ASD. 5. Have a severe hearing or visual impairment. 6. Participation in other clinical trials that may affect speech function. 7. Skin lesions or infection at the scalp treatment site. 8. The fontanelle has not yet closed. 9. Previous rTMS treatment in the last 3 months. 10. Developmental quotient \\\u003C 40 in any developmental domains; other circumstances that prevented cooperation with the study.","2 Years","5 Years",{"count":63,"type":22},50,[25],"This study explores a safe and effective new approach to improve language function in children with Global Developmental Delay (GDD). Conducted at Xiangxi Autonomous Prefecture People's Hospital, the study will recruit approximately 50 children aged 2 to 5 years. Participants will be randomly assigned to one of two groups: one receiving personalized language training combined with non-invasive, painless repetitive Transcranial Magnetic Stimulation (rTMS) to activate language regions of the brain, and a control group receiving personalized training for comparative analysis. The study spans one month, including a two-week intervention period followed by a two-week follow-up to evaluate the efficacy and sustainability of the combined therapy. This study has been rigorously reviewed and approved by the hospital's Ethics Committee.",[67,68,31,69],"Developmental Delay Disorder","Repetitive Transcranial Magnetic Stimulation (rTMS)","Language Disorders in Children","RECRUITING","2026-05-28",{"date":73,"type":44},"2026-06-02",{"date":75,"type":22},"2026-05-27",{"date":77,"type":22},"2026-12-31",{"name":79,"class":51},"Xiangya Hospital of Central South University",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":61,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":100,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":52},"100559587","register-for-patients-with-thyroid-hormone-resistance-100559587","NCT06566066","Register for Patients With Thyroid Hormone Resistance.","Deep Geno- and Phenotyping of Patients With Thyroid Hormone Resistance, a Register Study.","DEEPTYPE","Inclusion Criteria:\n\n* Presence of a coding or non-coding mutation in SLC16A2\n* Presence of a coding or non-coding mutation in THRA\n* Abnormal fT3\u002FfT4 ratio in the serum\n* Written informed consent of the caregivers for participation in the register study\n\nExclusion Criteria:\n\n* Withdrawal of consent\n* Correction\u002Fchange of the molecular diagnosis",{"count":89,"type":22},200,"OBSERVATIONAL","Thyroid hormones (TH) play a pivotal role in the development and function of the mammalian brain. Patients with impaired thyroid hormone transport into the brain tissue or in the case of defective local thyroid hormone receptor (collectively referred to as thyroid hormone resistance) subsequently experience psychomotor disabilities.\n\nThe \"DEEPTYPE\" registry has been established with the objective of intensifying the genotyping and, in particular, the neurological phenotyping of patients exhibiting deficiencies in either the thyroid hormone transporter (MCT8) or the thyroid hormone receptor alpha (THRα). The objective of this registry-based study is to enhance the diagnostic yield for MCT8 and THRα deficiencies by employing the serum fT3\u002FfT4 ratio as a more sophisticated screening parameter. Furthermore, the investigators will study the genomic regulation of both genes and attempt to identify further coding and non-coding mutations that result in TH resistance. The patient registry \"DEEPTYPE\" will document the retrospective and prospective clinical data of identified children in a comprehensive manner. This will enable the identification of three key groups: (i) patients with non-coding mutations, (ii) patients with milder phenotypes presenting only with a subset of symptoms seen in both \"classic\" conditions, and (iii) patients who are ready for clinical trials.",[93,31,94,95,96,97,98,99],"Hypothyroidism","Intellectual Disability","Dystonia","Muscle Hypotonia","Seizures","Allan-Herndon-Dudley Syndrome","Microcephalus",[101,102,103,104,105,106],"Thyroid hormone","Thyroid hormone resistance","MCT8","SLC16A2","THRA deficiency","Myelination","2024-08-20",{"date":109,"type":44},"2024-08-22",{"date":111,"type":44},"2021-07-01",{"date":113,"type":22},"2029-07-31",{"name":115,"class":51},"Charite University, Berlin, Germany"]